4-Pro-MET Stats & Data

Harm‑reduction justifications for the additions/edits below:

1) 4‑PrO‑MET is an O‑propionyl ester at the 4‑position and is reasonably expected to hydrolyze in vivo to 4‑HO‑MET (metocin), analogous to other 4‑O‑esters like 4‑AcO compounds and the 4‑PrO‑DMT precedent showing psychedelic‑like activity in animals. This supports treating 4‑PrO‑MET’s potency/duration as roughly in the 4‑HO‑MET range while starting lower. Evidence: 4‑HO‑MET human ranges/durations; psilocin/4‑AcO literature; 4‑PrO‑DMT receptor/HTR work.

2) Pellet variability and over/underdosing reports exist for European 15–20 mg tablets; several users describe a half‑pellet as anywhere from mild to very strong. This justifies a 2–3 mg allergy/test dose and slow titration, even if labeled tablets suggest higher single‑unit doses.

3) Users frequently report a ‘sneaky’ come‑up with waves, yawning and occasional nausea. This makes early redosing risky; waiting at least 90–120 minutes before any adjustment reduces overshooting. 4‑HO‑MET timings support a 20–60 min onset and multi‑hour plateau.

4) MAOIs (e.g., Syrian rue) with tryptamines are high‑risk: MAO inhibition potentiates monoaminergic effects and can precipitate hypertensive or serotonergic toxicity. TripSit and general psychedelic HR sources flag lithium and TCAs as dangerous with psychedelics; tramadol and DXM add serotonergic/seizure risk. An anecdotal Rue+4‑PrO‑MET report describes heavy body load and abnormal ‘electric jolts,’ underscoring risk variability.

5) Insufflation: For 4‑HO‑MET, intranasal use shortens total duration and makes onset more abrupt; users often report rougher come‑ups. With 4‑PrO‑MET there is no PK/safety data; given ester hydrolysis uncertainty and nasal irritation, oral titration is safer. If someone insists, keeping intranasal doses in the same ballpark as 4‑HO‑MET’s snorted range minimizes risk.

6) Reagent testing: Indole‑positive reagents (Ehrlich/DMAB) turn purple with indoles (tryptamines/lysergamides) but cannot distinguish specific analogs; multi‑reagent testing plus, where available, lab‑based drug checking is advised. Hi‑Ground’s materials explain Ehrlich’s indole reactivity; reagent‑testing community notes its limitations. Drug‑checking services publish routine findings and accept non‑opioid psychedelics.

7) Cannabis reliably potentiates visuals and can worsen anxiety/loops on the come‑up; multiple 4‑PrO‑MET users reported this, supporting a caution tag.

8) Tolerance: Classic psychedelics show rapid, short‑lived tolerance. Community consensus for 4‑subbed tryptamines suggests about half tolerance by ~3–5 days and near‑baseline in 7–14 days; spacing sessions reduces dose escalation and unpredictable responses. (Anecdotal; aligns with general tryptamine practice.)

9) Stimulants raise HR/BP and can magnify anxiety/thought loops when combined with psychedelics; TripSit flags stimulant+psychedelic combinations as higher‑risk. Keep environments cool and hydrate sensibly to reduce hyperthermia risk.

10) Emergency ‘trip aborts’: benzodiazepines blunt/terminate psychedelic effects but carry sedation and amnesia risk, especially if alcohol is present. This supports reserving them for severe agitation/panic, not routine co‑use. (General HR guidance reflected in TripSit’s materials for psychedelics.)

Practical notes: Because this is a novel ester, visually identical tablets can vary; use a 0.001 g scale and consider splitting/crushing to homogenize before weighing. Multi‑reagent test kits (Ehrlich + Hofmann/Ehmann + Marquis/Froehde) improve screening; only lab testing confirms identity. Avoid driving, hot environments, and complex tasks; arrange a calm setting and trusted sober support if uncertain.